Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin

European Journal of Clinical Pharmacology

Volumn 39, Issue 2, 1990, Pages 107-112

  Handeland, G F ^a   Abildgaard, U ^a   Holm, H A ^a   Arnesen, K E ^b  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

deep vein thrombosis; dose adjustment; Heparin; LMW heparin; plasma level

Indexed keywords

DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; MALE; MIDDLE AGE; THROMBOPHLEBITIS;

EID: 0025160385     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/BF00280041     Document Type: Article

References (39)

1. The molecular-weight dependence of the rate enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor Xia, Factor XIIa and kallikrein by antithrombin
2. Molecular weight dependency of the heparin potentiation of thrombin and activated factor X. Effect of heparin neutralization in plasma
3. On the molecular-weight-dependency of the anticoagulant activity of heparin
4. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin
5. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation
6. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
7. Relationship between antithrombotic and anticoagulant effect of low molecular weight heparin
8. An overview of clinical trials of low molecular weight heparin fractions
9. Prevention of postoperative thromboembolism in orthopedic surgery
10. Prospective double-blind comparison between Fragmin and conventional low-dose heparin: Thromboprophylactic effect and bleeding complications
11. Prevention of post-operative venous thromboembolism by a new low molecular weight heparin fraction
12. Enoxaparin LMW heparin: Its use in prevention of DVT following total hip replacement
13. Anticoagulant effect of a low molecular weight heparinoid (ORG 10172) in human volunteers and haemodialysis patients
14. On the evaluation of heparin and low molecular weight heparin in haemodialysis of chronic renal failure
15. Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients
16. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis
17. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
18. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis
19. A human pharmacological study comparing conventional heparin and low molecular weight heparin fragment
20. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously
21. What is the optimal dosage of LMW heparin in the SC treatment of deep venous thrombosis?
22. Simplified chromogenic substrate assay for low molecular weight heparin
23. Evaluation of an amidolytic heparin assay method. Increased sensitivity by adding purified antithrombin III
24. Roentgen diagnosis of venous thrombosis in the leg
25. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy
26. The antithrombotic effect of heparin in deep venous thrombosis: Relation to four heparin assays
27. Heparin treatment of dep venous thrombosis in 280 patients: Symptoms related to dosage
28. Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration
29. Heparin doses and major bleedings
30. Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding
31. Monitoring heparin treatment
32. Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin)
33. Low molecular weight heparin fraction PK 10169: A new therapeutic means for anticoagulant therapy?
34. Continous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis
35. Heparin therapy adjusted by bodyweight
36. Pharmacokinetics of intravenous and subcutaneously administered Fragmin in Healthy volunteers
37. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration